melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Discovery Services:
Our Technology

Click here to download the Melior Brochure        

Click here to download the Melior Models list           

theraTRACE

Melior Pharmaceuticals

 melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery management team


Andrew Reaume melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofilingAndrew G. Reaume, PhD, MBA..
President and CEO, Co-Founder

Dr. Reaume was previously a Senior Business Analyst at Pfizer, Inc. in the department of Genomics and Proteomic Sciences. There he spearheaded an initiative to create a platform for comprehensively characterizing (phenotyping) genetically modified mice and ran the collaboration involving a third party partnership to build it. This effort involved working closely with scientists throughout the global Pfizer organization, business development professionals, information technology specialists as well as the scientists and business development professionals at the partner company.

From 1993 to 1999, Dr. Reaume worked as a research scientist at Cephalon where he was principally involved in creating animal models of neurodegenerative disease. During this time Dr. Reaume worked closely on a number of projects with Dr. Saporito, co-founder of Melior. In addition to Dr. Reaume's research activities at Cephalon, he identified and helped coordinate three in-licensing opportunities.

In 2003, he received his MBA from the Wharton School where he graduated with honors in Entrepreneurial Management. He received his PhD in genetics from the University of Connecticut in 1990.

melior

Michael S. Saporito melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofilingMichael S. Saporito, PhD
Vice President of Research, Co-Founder

Dr. Saporito has spent the last 15 years in positions of increasing responsibility in the pharmaceutical industry. From 1991 to 2002, Dr. Saporito was Scientist at Cephalon Inc. in the Departments of Neurobiology and Pharmacology. At Cephalon, Dr. Saporito was the lead pharmacologist in the discovery of CEP-1347, a neuroprotective kinase inhibitor that reached Phase III clinical trials for Parkinson's disease. While at Cephalon, Dr. Saporito and Dr. Reaume collaborated on a number of projects involving molecular and cellular mechanisms of neurodegeneration.

From 2002 to 2004, Dr. Saporito was Group Leader in Biology at Locus Pharmaceuticals, a computational drug design company. In this role he led various preclinical programs targeting oncological, inflammatory and neurological therapeutic endpoints. Dr. Saporito has extensive experience with a wide variety of animal models of diseases encompassing inflammation, metabolic disease, neurological disorders and cancer.

Dr. Saporito received his Ph.D. in Pharmacology from the Philadelphia College of Pharmacy and Science (currently The University of Sciences of Philadelphia) and continued his postdoctoral studies at UMDNJ-Robert Wood Johnson Medical School under the direction of Dr. Richard Heikkila.


melior

SENIOR STAFF

Heather Hain melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofilingJohn R. Ciallella, Ph.D.
Director of Research Operations

Most recently, Dr. Ciallella was a Senior Research Scientist at Centocor, Inc., a Johnson & Johnson company.  Dr. Ciallella was responsible for establishing directives aimed at assessing the therapeutic value of biopharmaceuticals in nervous system disorders. Prior to joining Centocor, Dr. Ciallella was a Research Scientist at Cephalon, Inc., where he led the in vivo screening efforts to identify novel kinase inhibitors for the treatment of Alzheimer’s disease. 

Dr. Ciallella received his Ph.D. from the University of Kentucky Sanders Brown Center on Aging and Department of Microbiology and Immunology.  His postdoctoral training was at the University of Pittsburgh in the lab of Dr. Steven DeKosky, where he studied the biochemical links between traumatic brain injury and Alzheimer’s disease.  

melior

Heather Hain melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofilingJohn A. Gruner, Ph.D.
Director of Neurophysiology

Dr. Gruner was previously a Senior Scientist at Cephalon, Inc., where he designed and supervised neurophysiological and pharmacological studies involving numerous neurological disease areas. He has evaluated neuroprotection by trophic agents, free radical inhibitors, kinase inhibitors, and other compounds in neuropathy, neurodegeneration, and motor neuron disease models, and has elucidated mechanisms of action of proprietary analgesic agents. As head of a preclinical sleep research lab, he studied the actions of dopaminergic agents and other drugs in sleep and wake activity. He was a discovery team member for several sleep and wake enhancing and psychostimulant agents, including an H3 receptor antagonist currently in clinical development.

Dr. Gruner received his B.A. from UCSD and Ph.D. at Purdue Univ., where he investigated the role of the cerebellum in motor control. As a postdoctoral fellow and later Research Assistant Professor in the Dept. of Neurosurgery at NYU, he designed stimulation systems for paralyzed muscle, and implemented electrophysiological and behavior assays to evaluate treatment efficacy in the NYU spinal cord injury model he co-developed.

 

Back to top of page